---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-032950"
form_type: "8-K"
ticker: "APGE"
cik: "0001974640"
company_name: "Apogee Therapeutics, Inc."
filed_at: "2026-03-23T23:59:59+00:00"
generated_at: "2026-05-15T09:25:07.863767+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Apogee reports positive Phase 2 52-week zumilokibart data; durable maintenance with 3- and 6-month dosing

## Summary
- EASI-75 maintained in 75% (3-month) and 85% (6-month) of Week 16 responders; vIGA 0/1 maintained in 86% and 78%.
- Deepening of response across all endpoints over 52 weeks in the full zumilokibart-treated population.
- Safety profile consistent with class; common TEAEs: noninfective conjunctivitis (13.4%), URTI (12.6%), nasopharyngitis (9.2%).
- Part B 16-week induction data expected Q2 2026; Phase 3 initiation in 2H 2026; potential commercial launch in 2029.

## SEC filing metadata
- accession: 0001104659-26-032950
- form_type: 8-K
- ticker: APGE
- cik: 0001974640
- company_name: Apogee Therapeutics, Inc.
- filed_at: 2026-03-23T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1974640/000110465926032950/0001104659-26-032950-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1974640/000110465926032950/tm269553d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-032950
- JSON: https://secwatch.observer/filing/0001104659-26-032950.json
- Plain text: https://secwatch.observer/filing/0001104659-26-032950.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.